Abstracts tagged "axial spondyloarthritis"

Abstract Number: 2133 • 2018 ACR/ARHP Annual Meeting
Comparative Disease Burden of Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Data from the Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries
Philip J. Mease¹, Mei Liu², Sabrina Rebello³, Hyungjoo Kang², Yujin Park⁴ and Jeffrey Greenberg^2,5, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Southborough, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) are 3 common inflammatory rheumatic diseases that can lead to deformities and joint destruction;…
Abstract Number: 893 • 2018 ACR/ARHP Annual Meeting
Identification of Axial Spondyloarthritis Patients in a Large Dataset: The Development and Validation of Novel Methods
Rebecca S. Overbury¹, Shaobo Pei², Gopi Penmetsa², Grant W. Cannon², Daniel O. Clegg³, Brian Sauer⁴ and Jessica Walsh⁵, ¹Internal Medicine, Divison of Rheumatology, University of Utah Medical Center, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³Division of Rheumatology, University of Utah Medical Center, Salt Lake City, UT, ⁴Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁵Rheumatology, Salt Lake City Veterans Affairs, Salt Lake City, UT
Background/Purpose: Big data research in axial spondyloarthritis (axSpA) is limited by a lack of adequate methods for identifying axSpA patients, since there are no billing…
Abstract Number: 2537 • 2018 ACR/ARHP Annual Meeting
Benefit Study: Results of Interim Analysis of a Pan-European Observational Study to Evaluate Real-World Effectiveness of SB4 Following Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (AxSpA)
Klaus Krüger¹, Carlo Selmi^2,3, Alain Cantagrel⁴, Miguel A. Abad⁵, Ulrich Freudensprung⁶, Mourad Farouk Rezk⁶ and Janet Addison⁷, ¹Medical Centre of Rheumatology, Munich, Germany, ²Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, ³BIOMETRA Department, University of Milan, Milan, Italy, ⁴Center of Rheumatology of CHU, Toulouse, France, ⁵FEA Reumatología, Hospital Virgen del Puerto, Cáceres, Spain, ⁶Biogen International GmbH, Zug, Switzerland, ⁷Biogen Idec, Maidenhead, United Kingdom
Background/Purpose: SB4, a biosimilar to the reference ETN, received EU marketing authorisation in January 2016, based on the totality of evidence from pre-clinical and clinical…
Abstract Number: 644 • 2017 ACR/ARHP Annual Meeting
Association of Osteonectin, Osteopontin and Osteocalcin with Inflammation and Cardiovascular Risk in Patients with Axial Spondyloarthritis
Fernanda Genre¹, Javier Rueda-Gotor², Juan Irure-Ventura³, Sara Remuzgo-Martínez¹, Alfonso Corrales¹, Begoña Ubilla¹, Veronica Mijares¹, Carlos Fernández-Díaz¹, Virginia Portilla¹, Ricardo Blanco¹, Javier Llorca⁴, J. Gonzalo Ocejo-Vinyals³, Raquel López-Mejías¹ and Miguel Angel González-Gay⁵, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ³Immunology Division, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain, ⁵Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL and School of Medicine, University of Cantabria, Santander, Spain
Background/Purpose: A higher incidence of cardiovascular (CV) risk factors and atherosclerosis has been reported in axial spondyloarthritis (axSpA) patients1. Since axSpA (particularly AS) is an…
Abstract Number: 2516 • 2017 ACR/ARHP Annual Meeting
Trabecular Bone Score As an Assessment Tool to Identify the Risk of Osteoporosis in Axial Spondyloarthritis: A Case-Control Study
Kwi Young Kang, Internal Medicine, Catholic University of Korea, Seoul, Korea, Republic of (South)
Background/Purpose: The trabecular bone score (TBS) is a novel tool used to evaluate bone microarchitecture. It is a textural index that evaluates pixel gray-level variations…
Abstract Number: 1315 • 2017 ACR/ARHP Annual Meeting
Influence of Rheumatoid Arthritis and Axial Spondyloarthritis on Pregnancy Complications, Pregnancy Outcome and Delivery Mode
Frauke Förger¹, Stephanie van den Brandt², Astrid Zbinden³, Monika Ostensen³ and Peter M. Villiger³, ¹Inselspital, University of Bern, Bern, Switzerland, ²Clinical Immunology and Rheumatology, University of Amsterdam, Amsterdam, Netherlands, ³Rheumatology, Immunology and Allergology, Inselspital, University of Bern, Bern, Switzerland
Background/Purpose: To analyze pregnancy complications, pregnancy outcome and delivery mode in patients with rheumatoid arthritis (RA) and axial spondyloarthritis (axSpA).Methods: Patients with RA and axSpA…
Abstract Number: 2521 • 2017 ACR/ARHP Annual Meeting
Metabolic Syndrome Is Associated with Active Disease in Psoriatic Arthritis and May Contribute to Development of Syndesmophytes
Pervin Sanci¹, Gokce Kenar², Berrin Zengin², Sadettin Uslu³, Aydan Koken³, Handan Yarkan³, Gerçek Can³, Merih Birlik³ and Fatos Onen², ¹Internal Medicine, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ²Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ³Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey
Background/Purpose: An increased prevalence of metabolic syndrome (MetS) has been reported in psoriatic arthritis (PsA) suggesting an association between the inflammation and MetS. The aim…
Abstract Number: 1503 • 2017 ACR/ARHP Annual Meeting
The Prevalence of Axial Spondyloarthritis in Israel
Sara Borok Lev-Ran¹, Hagit Sarvagyl-Maman², Victoria Furer³, Sara Pel⁴, Iddo Drukman⁵, Gideon Flusser⁵ and Ori Elkayam⁶, ¹Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine,Tel Aviv University, Tel AViv, Israel, ²Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel-aviv, Israel, ³Rheumatology, Tel-Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel, ⁴Rheumatology, Sourasky Medical Center, Tel Aviv, Israel, ⁵Radiology, Tel Aviv Medical Center, Tel Aviv, Israel, ⁶Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Background/Purpose: The concept of axial Spondyloarthritis (SpA) as defined by the ASAS criteria is relatively new. While the prevalence of Ankylosing spondylitis is around 0.5%,…
Abstract Number: 2803 • 2017 ACR/ARHP Annual Meeting
Predictors of Remission Maintenance up to Week 68 and Successful Therapy Discontinuation in Patients with Non-Radiographic Axial Spondyloarthritis Who Achieved Sustained Remission on 28-Week Open-Label Adalimumab Treatment
Joachim Sieper¹, Robert B.M. Landewé², Marina N. Magrey³, Jaclyn K. Anderson⁴, Sheng Zhong⁴, Xin Wang⁴ and Apinya Lertratanakul⁴, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²University of Amsterdam, Amsterdam, Netherlands, ³Case Western Reserve University School of Medicine at MetroHealth Medical Center, Cleveland, OH, ⁴AbbVie Inc., North Chicago, IL
Background/Purpose: Sustained remission is an important treatment goal in patients (pts) with non-radiographic axial SpA (nr-axSpA). Factors predicting successful remission maintenance are unknown. We sought…
Abstract Number: 1507 • 2017 ACR/ARHP Annual Meeting
Comparison of the Clinical and Imaging Arms of the Assessment of Spondyloarthritis International Society Classification Criteria and Parameters of Objective Inflammation in Patients with Non-Radiographic Axial Spondyloarthritis
Robert B.M. Landewé¹, Joachim Sieper², Atul A. Deodhar³, Helena Marzo-Ortega⁴, Robert G. Lambert⁵, Mei Li⁶, Xin Wang⁶ and Jaclyn K. Anderson⁶, ¹University of Amsterdam, Amsterdam, Netherlands, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Oregon Health & Science University, Portland, OR, ⁴NIHR LBRC, Leeds Teaching Hospitals Trust and LIRMM, University of Leeds, Leeds, United Kingdom, ⁵University of Alberta, Edmonton, AB, Canada, ⁶AbbVie Inc., North Chicago, IL
Background/Purpose: Assessment of SpondyloArthritis international Society (ASAS) recommendations for use of TNF inhibitors (TNFi) in axial SpA include active disease and a positive expert opinion,…
Abstract Number: 1513 • 2017 ACR/ARHP Annual Meeting
Clinical Characteristics and Peripheral Joint Involvement at the Time of Diagnosis of Non-Radiographic Axial Spondyloarthritis Patients in the United States and Europe
Atul A. Deodhar¹, Theresa Hunter², David Sandoval Calderon³, Steve Lobosco⁴, Rachel Moon⁴ and Gary Milligan⁵, ¹Oregon Health & Science University, Portland, OR, ²Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, IN, ³Eli Lilly and Company, Indianapolis, IN, ⁴Adelphi Real World, Macclesfield, United Kingdom, ⁵Adelphi Real World, Macclesfield,, United Kingdom
Background/Purpose: Timely identification of nr-axSpA may lead to earlier intervention to reduce symptoms, improve function, and reduce disease burden. The purpose of this study was…
Abstract Number: 1515 • 2017 ACR/ARHP Annual Meeting
Improvements in Enthesitis Scores with Certolizumab Pegol Treatment in Males and Females with Active Axial Spondyloarthritis Are Maintained to Week 204
Maxime Dougados¹, Philip J Mease², Joachim Sieper³, Peter C. Taylor⁴, Natasha de Peyrecave⁵, Tommi Nurminen⁶ and Jürgen Braun⁷, ¹Rheumatology Department, Paris-Descartes University and Cochin Hospital, Paris, France, ²Swedish Medical Center and University of Washington, Seattle, WA, ³Charité University Hospital, Berlin, Germany, ⁴Nuffield Dept. of Orthopaedics, Rheumatology and Musculoskeletal, Sciences, Kennedy Institute of Rheumatology, University of Oxford,, Oxford, United Kingdom, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB Pharma, Monheim, Germany, ⁷Rheumazentrum Ruhrgebiet, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA), characterized by spinal inflammation, is also associated with extra-spinal manifestations including inflammation of the entheses (enthesitis). Enthesitis is equally prevalent throughout…
Abstract Number: 1566 • 2017 ACR/ARHP Annual Meeting
Elevated IL-1 Expression Levels in Mesenchymal Stem Cells Derived from Spondyloarthitis Patients Might be Linked to Increased Osteoblast Mineralization
Gerlinde Layh-Schmitt¹, Breanna Nguyen¹, Emily Lazowick¹, Stephen R. Brooks² and Robert Colbert¹, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²NIAMS/NIH, Biodata Mining & Discovery, Bethesda, MD
Background/Purpose: Axial spondyloarthritis (AxSpA) is an immune–mediated inflammatory disease involving the spine and sacroiliac joint. AxSpA is characterized by vertebral trabecular bone loss and progressive…
Abstract Number: 1573 • 2017 ACR/ARHP Annual Meeting
In Vivo Phosphorylation of p38 in Monocytes Is Enhanced in Patients with Axial Spondyloarthritis (axSpA) at the Time of Diagnosis
Antti Kuuliala^1,2, Krista Kuuliala^1,3, Riitta Koivuniemi^2,4, Mari Hämäläinen⁵, Eeva Moilanen⁶, Hannu Kautiainen⁷, Heikki Repo^1,3 and Marjatta Leirisalo-Repo^2,4, ¹Bacteriology and Immunology, University of Helsinki, Helsinki, Finland, ²Rheumatology, Helsinki University Hospital, Helsinki, Finland, ³Helsinki University Hospital, Helsinki, Finland, ⁴Rheumatology, University of Helsinki, Helsinki, Finland, ⁵The Immunopharmacology Research Group, University of Tampere School of Medicine and Tampere University Hospital, Tampere, Finland, ⁶The Immunopharmacology Research Group, Faculty of Medicine and Life Sciences, University of Tampere and Tampere University Hospital, Tampere, Finland, Tampere, Finland, ⁷Unit of Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Background/Purpose: Host response to microbes is considered to contribute to the pathogenesis to axSpA and other HLA-B27 associated diseases. The p38 MAP kinase pathway plays…
Abstract Number: 1787 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Continuing Versus Withdrawing Adalimumab in Maintaining Remission in Patients with Non-Radiographic Axial Spondyloarthritis
Robert B.M. Landewé¹, Joachim Sieper², Philip J Mease³, Robert D Inman⁴, Xin Wang⁵, Mei Li⁵, Aileen L. Pangan⁵ and Jaclyn K. Anderson⁵, ¹University of Amsterdam, Amsterdam, Netherlands, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Swedish Medical Center and University of Washington, Seattle, WA, ⁴Department of Immunology, University of Toronto, Toronto, ON, Canada, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: It is not known whether TNF blockers can be stopped in non-radiographic (nr-axSpA) patients who are in remission. In ABILITY-1, adalimumab (ADA) significantly improved…

« Previous Page
1
…
8
9
10
11
12
…
16
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.